Safety Triggers — Fat Loss: Lipolysis

Immediate Effects (3)

Long-Term Risks (5)

Sourcing Dangers (4)

Contraindications (6)

Pregnancy and Breastfeeding

Strictly contraindicated. Animal data showed hydrocephaly in offspring at doses 2–4 times the clinical human dose. No benefit to pregnant users.

Avoid

Active Malignancy

GH stimulation can promote tumor growth. Any form of active cancer is an absolute contraindication for GH-axis peptides.

Avoid

Pituitary Disorders

Contraindicated for those with disruption of the hypothalamic-pituitary axis due to tumors, surgery, head radiation, or trauma.

Avoid

CYP450-Metabolized Medications

GH may alter the clearance of compounds metabolized by cytochrome P450 liver enzymes (e.g., corticosteroids, anticonvulsants). Dose adjustments may be needed.

Warning

Hypoadrenalism on Glucocorticoids

Users may require increased maintenance doses of glucocorticoids if they have previously diagnosed hypoadrenalism.

Warning

Competitive Athletics

Many GH-axis peptides are prohibited in organized sport. Athletes must check anti-doping regulations before use.

Warning

Auto-Generated Safety Flags

BLOCK: User is pregnant or breastfeeding → do not recommend any GH-axis peptide

BLOCK: User has active malignancy or cancer history → do not recommend GH-stimulating peptides without oncologist clearance

WARN: User is pre-diabetic or diabetic (HbA1c ≥ 5.7%) → GH-axis peptides may worsen insulin resistance (HR 3.3 for diabetes with tesamorelin)

WARN: User mentions 'research chemical' or unregulated sourcing → flag contamination risk (heavy metals, incorrect concentrations documented)

INFO: AOD-9604, BPC-157, CJC-1295, Ipamorelin, TB-500 are FDA Category 2 as of late 2023 → compounding prohibited for human use

WARN: User on peptide therapy > 6 months → 50% antibody development rate observed with tesamorelin at 26 weeks; monitor for reduced efficacy

WARN: User on corticosteroids, anticonvulsants, or CYP450-metabolized drugs → GH may alter drug clearance; consult prescriber